News & Perspective

Mar 08, 2019

Mar 08, 2019

ASP Scan (Weekly) for Mar 08, 2019

Home therapy for kids' cellulitis
Antibiotics and UTI relapse
Outpatient surgery overprescribing
Resistance prevalence and sepsis
Resistant gonorrhea strain
Empiric antibiotics and UTI
Surgery-linked resistant Pseudomonas
Preventing healthcare-related infection
Resistance and sustainable development
New CARB-X funding
ESBL prediction models

Nov 30, 2018

Nov 30, 2018

ASP Scan (Weekly) for Nov 30, 2018

Superbugs in Canadian ICUs
Probiotics and ESBL colonization
Antibiotics after rhinoplasty
Rapid flu diagnostic tests
CDC funding for AMR initiatives
VRE, MRSA co-colonization in nursing homes
UV disinfection for C diff
Fluoroquinolones and aortic rupture risk
Resistance action plan
Deaths from MDROs
Stewardship in a Japanese hospital
Stewardship study quality

Aug 16, 2007

Aug 16, 2007

Glaxo sells more H5N1 vaccine to US, launches trial

(CIDRAP News) – The British pharmaceutical company GlaxoSmithKline (GSK) recently announced another major order of prepandemic H5N1 influenza vaccine from the US Department of Health and Human Services (HHS), along with plans to launch a North American clinical trial of the vaccine.

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»